Arrowhead announces Australian TGA approved Redemplo for FCS

Arrowhead (ARWR) Pharmaceuticals announced that the Australian Therapeutic Goods Administration, TGA, has approved Redemplo, a small interfering RNA medicine, as an adjunct to diet to reduce triglyceride levels for adult patients with familial chylomicronemia syndrome, FCS, for whom standard triglyceride lowering therapies have been inadequate. FCS is a severe, rare disease characterized by triglyceride levels that can be orders of magnitude higher than normal, leading to a substantially higher risk of developing acute, recurrent, and potentially fatal pancreatitis. “We are pleased that Redemplo is now the first-ever approved treatment for Australians living with genetic or clinical FCS,” said Christopher Anzalone, Ph.D., President and CEO of Arrowhead Pharmaceuticals. “This approval underscores the strength of the clinical data and the ability of our TRiM platform to develop targeted siRNA therapies to potentially reach multiple tissues and disease areas. We believe Redemplo could represent an important medicine for the FCS community in Australia, and we are working to bring this therapy to more patients as quickly as possible.”